Señales en vivo de EVG.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 abr 2024 @ 11:24):

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases...

Stats
Volumen de hoy	10.75M
Volumen promedio	1.25M
Capitalización de mercado	3.42M
EPS	£0 ( 2024-04-19 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.800
ATR14	£0 (0.00%)

Evgen Pharma PLC Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Evgen Pharma PLC Finanzas

Annual	2022
Ingresos:	£442 000
Beneficio Bruto:	£429 000 (97.06 %)
EPS:	£-0.0147

FY	2022
Ingresos:	£442 000
Beneficio Bruto:	£429 000 (97.06 %)
EPS:	£-0.0147

FY	2022
Ingresos:	£0
Beneficio Bruto:	£0 (0.00 %)
EPS:	£-0.00990

FY	2021
Ingresos:	£194 000
Beneficio Bruto:	£0.00 (0.00 %)
EPS:	£-0.0279

Financial Reports:

No articles found.

Evgen Pharma PLC

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.